DHX9-mediated pathway contributes to the malignant phenotype of myelodysplastic syndromes

Nanfang Huang(Shanghai Jiao Tong University), Feng Xu(Nanchang University)
iScience
May 26, 2023
10.1016/j.isci.2023.106962
Cited by 9

Related Papers

Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome
|Scientific Reports|2014|49
Interleukin‐17 enhances the production of interferon‐γ and tumour necrosis factor‐α by bone marrow <scp>T</scp> lymphocytes from patients with lower risk myelodysplastic syndromes
|European Journal Of Haematology|2013|36
Genomic loss of EZH2 leads to epigenetic modifications and overexpression of the HOX gene clusters in myelodysplastic syndrome
|Oncotarget|2016|34